Cargando…

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis

Detalles Bibliográficos
Autores principales:	Santoni, Adele, Malchiodi, Margherita, Zappone, Elisabetta, Sicuranza, Anna, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317831/ https://www.ncbi.nlm.nih.gov/pubmed/37198324 http://dx.doi.org/10.1038/s41375-023-01930-z

Ejemplares similares

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
por: Minetto, Paola, et al.
Publicado: (2023)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Anterior Cruciate Ligament Reconstruction Using Fixed Loop All-Inside (FLAI) Technique
por: Gawish, Hesham Mohamed, et al.
Publicado: (2023)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

The nucleotide‐dependent interaction of FlaH and FlaI is essential for assembly and function of the archaellum motor
por: Chaudhury, Paushali, et al.
Publicado: (2015)

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020)

Omitted Acknowledgment
Publicado: (2020)

Reference Omitted
Publicado: (2023)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

The relationships between FLAIS, a novel insulin sensitivity index, and cardiovascular risk factors in a population-based study
por: Karczewska-Kupczewska, Monika, et al.
Publicado: (2022)

CD26/DPP-4 in Chronic Myeloid Leukemia
por: Sicuranza, Anna, et al.
Publicado: (2022)

Should Intercepting Traps Be Omitted?
Publicado: (1912)

Advances in therapeutic options for newly diagnosed, high-risk AML patients
por: Doucette, Kimberley, et al.
Publicado: (2021)

Characterization of the ATPase FlaI of the motor complex of the Pyrococcus furiosus archaellum and its interactions between the ATP-binding protein FlaH
por: Chaudhury, Paushali, et al.
Publicado: (2018)

Omitted doses as an unintended consequence of a hospital restricted antibacterial system: a retrospective observational study
por: Powell, Neil, et al.
Publicado: (2015)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Electrophysiological response to omitted stimulus in sentence processing
por: Nakano, Hiroko, et al.
Publicado: (2014)

Omitted Information on Data and Safety Monitoring Board
Publicado: (2022)

Omit needless words: Sentence length perception
por: Matthews, Nestor, et al.
Publicado: (2023)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients
por: Fiorino, Fabio, et al.
Publicado: (2022)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

P568: COMPARISON OF VENETOCLAX-BASED INDUCTION THERAPY OR 3 + 7 FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AML PATIENTS
por: Tan, Tran-Der, et al.
Publicado: (2023)

Frozen section utilization to omit systematic biopsy in diagnosing high risk prostate cancer
por: Tae, Jong Hyun, et al.
Publicado: (2022)

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review
por: Hao, Qiukui, et al.
Publicado: (2022)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
por: Fiorino, Fabio, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Omitting histopathology in wrist ganglions. A risky proposition
por: Zubairi, Akbar J., et al.
Publicado: (2016)

Welfare Consequences of Omitting Beak Trimming in Barn Layers
por: Riber, Anja B., et al.
Publicado: (2017)

GoldCLIP: Gel-omitted Ligation-dependent CLIP
por: Gu, Jiaqi, et al.
Publicado: (2018)

Note Omitted in Dr Stratton's Paper, Page 270
Publicado: (1849)

Omitted Description of and Citation to Previously Published Related Study
Publicado: (2020)

Oral health omitted from Early Years Review
Publicado: (2021)

Oral health omitted from Early Years Review
Publicado: (2021)

A Chapter Omitted in Most Treatises on General Pathology
Publicado: (1856)

Omitted Author, Funding Information, and Study Group Members
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tv0eilv8b7535cvj582j5umnge